All LimmaTech Biologics AG articles
-
NewsValneva and LimmaTech team up to accelerate tetravalent Shigella vaccine candidate
Valneva SE and LimmaTech Biologics AG have entered into a strategic partnership and exclusive licensing agreement for the development, manufacturing and commercialization of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.